Global Big Pharma Partnering Terms and Agreements 2014-2019 Deal trends, players and financials

Be the first to review this product

Availability: In stock

$2,995.00
Global Big Pharma Partnering Terms and Agreements 2014-2019 Deal trends, players and financials
Publication date Mar 2019
Publisher Current Partnering
Number of pages 1000+
Report edition 3
Product code CP1010
ISBN n/a
Product type Research report
Available formats PDF

OR

Global Big Pharma Partnering Terms and Agreements 2014 to 2019 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

 

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.

 

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

 

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Big Pharma deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

 

Key benefits

 

Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

 

  • In-depth understanding of Big Pharma deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2014
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

 

Big Pharma Partnering Terms and Agreements includes:

       

  • Trends in Big Pharma dealmaking in the biopharma industry since 2014
  • Analysis of Big Pharma deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Big Pharma deals
  • Access to Big Pharma contract documents
  • Leading Big Pharma deals by value since 2014
  • Most active Big Pharma dealmakers since 2014

 

In Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 3,000 Big Pharma deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Big Pharma Partnering 2014-2019: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

 

  • In-depth understanding of Big Pharma deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2014
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Big Pharma dealmaking

 

2.1. Introduction

2.2. Big Pharma partnering over the years

2.3. Most active Big Pharma dealmakers

2.4. Big Pharma partnering by deal type

2.5. Big Pharma partnering by therapy area

2.6. Big Pharma partnering by technology type

2.7. Deal terms for Big Pharma partnering

2.7.1 Big Pharma partnering headline values

2.7.2 Big Pharma deal upfront payments

2.7.3 Big Pharma deal milestone payments

2.7.4 Big Pharma royalty rates

 

Chapter 3 – Leading Big Pharma deals

 

3.1. Introduction

3.2. Top Big Pharma deals by value

 

Chapter 4 – Most active Big Pharma dealmakers

 

4.1. Introduction

4.2. Most active Big Pharma dealmakers

4.3. Most active Big Pharma partnering company profiles

Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

 

Chapter 5 – Big Pharma contracts dealmaking directory

 

5.1. Introduction

5.2. Big Pharma contracts dealmaking directory

 

Chapter 6 – Big Pharma dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Big Pharma deals by company A-Z

Appendix 2 – Big Pharma deals by stage of development

Appendix 3 – Big Pharma deals by deal type

Appendix 4 – Big Pharma deals by therapy area

Appendix 5 – Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Big Pharma partnering since 2014

Figure 2: Active Big Pharma dealmaking activity since 2019

Figure 3: Big Pharma partnering by deal type since 2014

Figure 4: Big Pharma partnering by disease type since 2014

Figure 5: Big Pharma partnering by technology type since 2014

Figure 6: Big Pharma deals with a headline value

Figure 7: Big Pharma deals with an upfront value

Figure 8: Big Pharma deals with a milestone value

Figure 9: Big Pharma deals with a royalty rate value

Figure 10: Top Big Pharma deals by value since 2014

Figure 11: Most active Big Pharma dealmakers since 2019

Figure 12: Online partnering resources

Figure 13: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,485: single site license
  • $17,475: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Write Your Own Review

Only registered users can write reviews. Please, log in or register

© 2019 Wildwood Ventures Ltd.